Strategies for combating persister cell and biofilm infections

Thomas K. Wood*
Department of Chemical Engineering, Pennsylvania State University, University Park, Pennsylvania, 16802-4400, PA, USA.

Summary

Bacterial cells are constantly exposed to environmental stress; for example, almost all cells must endure starvation, and antimicrobials, of course, are administered to kill bacteria. These stressed cells enter a resting state known as persistence in which they become tolerant to nearly all antibiotics without undergoing genetic change. These dormant cells survive courses of antibiotics, as antibiotics are most effective against actively metabolizing cells, and reconstitute infections. In humans, most of these bacterial infections occur in biofilms in which bacteria attach to one another via secreted proteins, polysaccharides and even DNA. Herein, biotechnological methods are described to combat persister cells and to eradicate biofilms by understanding the genetic basis of both phenomena.

Sustainable development goal and scope

As bacteria evolve resistance to all antimicrobials and even compounds that prevent them from communicating (Maeda et al., 2012), the goal is to develop new, sustainable techniques for treating bacterial infections by understanding how persister cells and biofilms form. Furthermore, the cost of all biofilm/persister infections to society is substantial; for example, 17 million new biofilm infections occur every year in the United States, and of these infections, 550 000 people die (Wolcott and Dowd, 2011). In addition, biofilm infections add more than $1B to the cost of hospital stays (Percival et al., 2011) as bacterial infections have been found for most if not all medical devices (Bryers, 2008) and surgical removal is the only recourse. Furthermore, 1–2% of those in developed countries will develop chronic skin wounds, which cost $25B annually in the United States alone (Percival et al., 2011).

Combating persister cells

Persister cells survive the stress of antibiotic treatment due to their lack of metabolism, rather than through genetic change, as shown via four seminal experiments conducted by the discoverers of the phenotype (Hobby et al., 1942; Bigger, 1944); later, once the antibiotic is removed, the cells can reconstitute infections. Subsequent research corroborated that persister cells are metabolically inactive; for example, Shah et al. (2006) found that metabolically inactive cells were more tolerant to the fluoroquinolone ofloxacin, and Kwan et al. (2013) found that cells lacking protein synthesis become persister cells, via pretreatment with rifampicin to stop transcription, with tetracycline to stop translation or with carbonyl cyanide m-chlorophenylhydrazone to halt ATP production. These three pretreatments convert an initial population of 0.01% persisters to up to approximately 80% persisters (a 10 000-fold increase in persister cells). Recent evidence has confirmed the importance of reducing protein production in persistence by demonstrating that the persister cells have sharply reduced ATP levels (Conlon et al., 2016). Hence, persister cells are predominantly dormant.

As persister cells are dormant and resistant to traditional antibiotics (e.g. fluoroquinolones, aminoglycosides and β-lactams), microbial biotechnological approaches have been developed to kill sleeping cells. These approaches must utilize compounds that enter the cell without the need of active transport and kill the persister cells without requiring any cell machinery (as there is little or no metabolism). Examples of this approach include utilizing the DNA-cross-linking agents mitomycin C (Kwan et al., 2015) and cisplatin (Chowdhury et al., 2016); both compounds are approved for human use as cancer treatments by the U.S. Food and Drug Administration (FDA) and hold great promise for treating persistent infections, such as those related to wounds, because they have been shown to be effective for a wide range of infections including those of commensal...
of the matrix Staphylococcus epidermidis, Escherichia coli, Yersinia pestis and P. fluorescens biofilms, dispersin B can degrade these biofilms as well (Itoh et al., 2005). Showing the promise of this biotechnological approach, DNase is in clinical use for disrupting P. aeruginosa biofilms and dispersin B is also a possible therapeutic enzyme (Baker et al., 2016).

As persister cells frequently arise in biofilms (Lewis, 2008), it is important to treat both persister cells in suspension and within biofilms; this has been shown to be possible with compounds like cis-decanoic acid, which causes a 3000-fold reduction in the persister cells of the opportunistic pathogen P. aeruginosa in planktonic cultures along with a million-fold reduction in biofilm-derived persisters (Marques et al., 2014). Similarly, mitomycin C eliminates pathogenic E. coli and S. aureus in both suspension and biofilms (Kwan et al., 2015), and cisplatin eradicates P. aeruginosa persister cells in both biofilms and suspension (Chowdhury et al., 2016). Furthermore, some compounds have been discovered that both remove biofilms as well as kill persisters; for example, halogenated phenazines remove biofilms of S. aureus as well as kill its persister cells (Garrison et al., 2015).

The main challenge for these biotechnological discoveries is translating these laboratory developments into clinical use. To date, only a handful of antibiofilm compounds have been shown to be efficacious with humans. For example, 5-fluorouracil was utilized successfully in a human trial (Walz et al., 2010) and was given FDA approval for use to prevent biofilm formation on catheters (Angiotech Pharmaceuticals); 5-fluorouracil was discovered by screening 6,000 P. aeruginosa mutants for changes in biofilm formation and works by reducing cell communication (Ueda et al., 2009). 5-Fluorouracil was initially an FDA-approved for treating cancer (like mitomycin C and cisplatin), which illustrates another promising approach: repurposing drugs for antipersister and antibiotic use (Soo et al., 2017). Therefore, given these exciting discoveries for treating the most recalcitrant infections, one can be sanguine about our ability to continue to make use of biotechnology for combating infections.

Acknowledgements

This work was supported by the Army Research Office (W911NF-14-1-0279) and funds derived from the Biotechnology Endowed Professorship at the Pennsylvania State University.

Conflict of interest

None declared.
References

Allison, K.R., Brynildsen, M.P., and Collins, J.J. (2011) Metabolite-enabled eradication of bacterial persisters by aminoglycosides. *Nature* 473: 216–220.

Baker, P., Hill, P.J., Snarr, B.D., Alnabalseya, N., Pestrak, M.J., Lee, M.J., et al. (2016) Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent *Pseudomonas aeruginosa* biofilms. *Science Advances* 2: e1501632.

Bigger, J.W. (1944) Treatment of staphylococcal infections with penicillin by intermittent sterilisation. *The Lancet* 244: 497–500.

Branda, S.S., Vík, A., Friedman, L., and Kolter, R. (2005) Biofilms: the matrix revisited. *Trends Microbiol* 13: 20–26.

Bryers, J.D. (2008) Medical biofilms. *Biotechnol Bioeng* 100: 1–18.

Chowdhury, N., Wood, T.L., Martinez-Vázquez, M., García-Contreras, R., and Wood, T.K. (2016) DNA-crosslinker cislipasin eradicates bacterial persister cells. *Biotechnol Bioeng* 113: 1984–1992.

Conlon, B.P., Rowe, S.E., Gandt, A.B., Nuxoll, A.S., Donegan, N.P., Zalis, E.A., et al. (2016) Persister formation in *Staphylococcus aureus* is associated with ATP depletion. *Nature Microbiology* 1: 16051.

Feng, J., Auwaerter, P.G., and Zhang, Y. (2015) Drug combinations against *Borrelia burgdorferi* persisters in *vivo*: eradication achieved by using dapтомycin, cefoperazone and doxycycline. *PLoS One* 10: e0117207.

Fong, J.N. and Yildız, F.H. (2015) Biofilm matrix proteins. *Microbiol Spec* 3: MB-0004-2014.

Franklin, M.J., Nivens, D.E., Weadge, J.T., and Howell, P.L. (2011) Biosynthesis of the *Pseudomonas aeruginosa* extracellular polysaccharides, alginate, Pel, and Psl. *Front Microbiol* 2: 167.

Garrison, A.T., Abouelhassan, Y., Kalifidas, D., Bai, F., Ukhanoval, M., Mai, V., et al. (2015) Halogenated phenazines that potently eradicate biofilms, MRSA persister cells in non-biofilm cultures, and mycobacterium tuberculosis. *Angew Chem Int Ed* 54: 14819–14823.

Hobby, G.L., Meyer, K., and Chaffee, E. (1942) Observations on the mechanism of action of penicillin. *Experimental Biology and Medicine* 50: 281–285.

Itoh, Y., Wang, X., Hinnebusch, B.J., Preston, J.F. 3rd, and Romeo, T. (2005) Depolymerization of beta-1,6-N-acetyl-D-glucosamine disrupts the integrity of diverse bacterial biofilms. *J Bacteriol* 187: 382–387.

Jennings, L.K., Storek, K.M., Ledvina, H.E., Coulon, C., Marmion, L.S., Sadovskaya, I., et al. (2015) Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the *Pseudomonas aeruginosa* biofilm matrix. *Proc Natl Acad Sci USA* 112: 11353–11358.

Kaplan, J.B. (2010) Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. *J Dent Res* 89: 205–218.

Karatan, E., and Watnick, P. (2009) Signals, regulatory networks, and materials that build and break bacterial biofilms. *Microbiol Mol Biol Rev* 73: 310–347.

Kwan, B.W., Valenta, J.A., Benedik, M.J., and Wood, T.K. (2013) Arrested protein synthesis increases persister-like cell formation. *Antimicrob Agents Chemother* 57: 1468–1473.

Kwan, B.W., Chowdhury, N., and Wood, T.K. (2015) Combating bacterial infections by killing persister cells with mitomycin C. *Environ Microbiol* 17: 4406–4414.

Lewis, K. (2008) Multidrug tolerance of biofilms and persister cells. *Curr Top Microbiol Immunol* 322: 107–131.

Lister, J.L., and Horswill, A.R. (2014) *Staphylococcus aureus* biofilms: recent developments in biofilm dispersal. *Front Cell Infect Microbiol* 4: 178.

Maeda, T., García-Contreras, R., Pu, M., Sheng, L., García, L.R., Tomás, M., and Wood, T.K. (2012) Quorum quenching quandary: resistance to antivirulence compounds. *ISME J* 6: 493–501.

Marques, C.N.H., Morozov, A., Planzos, P., and Zelaya, H.M. (2014) The fatty acid signaling molecule cis-2-deconolic acid increases metabolic activity and reverts persister cells to an antimicrobial-susceptible state. *Appl Environ Microbiol* 80: 6976–6991.

Percival, S.L., Hill, K.E., Malic, S., Thomas, D.W., and Williams, D.W. (2011) Antimicrobial tolerance and the significance of persister cells in recalcitrant chronic wound biofilms. *Wound Repair and Regeneration* 19: 1–9.

Ramasubbu, N., Thomas, L.M., Ragunath, C., and Kaplan, J.B. (2005) Structural analysis of dispersin B, a biofilm-releasing glycoside hydrolase from the periodontopathogen *Actinobacillus actinomycetemcomitans*. *J Mol Biol* 349: 475–486.

Shah, D., Zhang, Z., Khodursky, A.B., Kaldalu, N., Kurg, K., and Lewis, K. (2006)Persisters: a distinct physiological state of *E. coli*. *BMC Microbiol* 6: 53.

Soo, V.W.C., Kwan, B.W., Quezada, H., Castillo-Juarez, I., Perez-Eretza, B., Garcia-Contreras, S.J., et al. (2017) Repurposing of anticancer drugs for the treatment of bacterial infections. *Curr Top Med Chem* 17: 1157–1176.

Ueda, A., Attila, C., Whiteley, M., and Wood, T.K. (2009) Uracil influences quorum sensing and biofilm formation in *Pseudomonas aeruginosa* and fluorouracil is an antagonist. *Microbiol Biotechnol* 2: 62–74.

Walz, J.M., Avelar, R.L., Longtime, K.J., Carter, K.L., Merrell, L.A., and Heard, S.O. (2010) Anti-infective external coating of central venous catheters: a randomized, noninferiority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization. *Crit Care Med* 38: 2095–2102.

Whitchurch, C.B., Tolker-Nielsen, T., Ragas, P.C., and Matick, J.S. (2002) Extracellular DNA required for bacterial biofilm formation. *Science* 295: 1487.

Wolcott, R., and Dowd, S. (2011) The role of biofilms: are we hitting the right target? *Plast Reconstr Surg* 127: 285–355.

Yu, S., Su, T., Wu, H., Liu, S., Wang, D., Zhao, T., et al. (2015) PslG, a self-produced glycosyl hydrolase from the periodontopathogen *Actinobacillus actinomycetemcomitans*. *PLoS One* 10: e0117207.

Yu, S., Su, T., Wu, H., Liu, S., Wang, D., Zhao, T., et al. (2015) PslG, a self-produced glycosyl hydrolase from the periodontopathogen *Actinobacillus actinomycetemcomitans*. *PLoS One* 10: e0117207.